Spartalizumab
Esophageal Squamous Cell Carcinoma
Explore 64 assets in Esophageal Squamous Cell Carcinoma →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
SOLTI Breast Cancer Research Group
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04802876CT.gov Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | — | Active Not Recruiting | — | — | — |
NCT04000529CT.gov Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | — | Terminated | — | — | — |
NCT01351103CT.gov A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Spartalizumab (this asset) | SOLTI Breast Cancer Research Group | P2 | CCC · 50 |
| Fluorouracilum | AstraZeneca | P3 | BB |
| Irinotecan | Taiho Oncology, Inc. | P2 | BB |
| Levofolinic Acid | Taiho Oncology, Inc. | P3 | BB |
| Oxaliplatin | Taiho Oncology, Inc. | P3 | B |
| Cetuximab | Hummingbird Bioscience | P2 | B |
| Pembrolizumab | GV20 Therapeutics | P3 | B |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P3 | B |
| Capecitabine | Chongqing University Cancer Hospital | P2 | B |
+42 more in the Esophageal Squamous Cell Carcinoma cohort
Other indications for Spartalizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P3 | B · 57 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 54 |
| Melanoma | — | P3 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Spartalizumab in Esophageal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/spartalizumab-esophageal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →